Ultragenyx Earnings

The next earnings date for Ultragenyx is July 31, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Ultragenyx Earnings

Report DateEstimated Earnings Per Share
11/04/2025$-1.29
07/31/2025$-1.28

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Ultragenyx Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
04/30/2025Before Market$-1.5710.29%
02/13/2025After Market$-1.39-9.45%
11/05/2024After Market$-1.403.45%
08/01/2024After Market$-1.5210.06%
05/02/2024After Market$-2.03-17.34%
02/15/2024After Market$-1.526.17%
11/02/2023After Market$-2.23-7.21%
08/03/2023After Market$-2.25-8.70%
05/04/2023After Market$-2.33-17.68%
02/16/2023After Market$-2.16-0.93%
11/02/2022After Market$-3.50-93.37%
07/28/2022After Market$-2.26-29.14%
05/05/2022After Market$-2.19-24.43%
02/10/2022After Market$-1.79-33.58%
11/02/2021After Market$-1.0823.40%
08/02/2021After Market$-1.81-36.09%
05/04/2021After Market$-2.03-63.71%
02/11/2021After Market$-0.3767.83%
10/27/2020After Market$-1.1310.32%
07/30/2020After Market$0.41126.62%
05/06/2020After Market$-1.91-13.69%
02/13/2020After Market$-1.621.82%
11/05/2019After Market$-1.96-16.67%
08/01/2019After Market$-1.89-11.18%
05/06/2019After Market$-1.82-4.60%
02/19/2019After Market$-1.733.35%
11/05/2018After Market$-1.7411.22%
08/02/2018After Market$-1.0649.28%
05/07/2018After Market$-2.03-968.42%
02/20/2018After Market$-1.895.03%
11/02/2017After Market$-1.87-0.54%
07/27/2017After Market$-1.720.58%
05/04/2017After Market$-1.634.68%
02/16/2017After Market$-1.75-1.74%
11/07/2016After Market$-1.64-7.19%
08/08/2016After Market$-1.46-1.39%
05/09/2016After Market$-1.35-4.65%
02/25/2016After Market$-1.42-24.56%
11/09/2015After Market$-1.03-18.39%
08/13/2015After Market$-0.83-31.75%
05/11/2015After Market$-0.63-16.67%
03/25/2015After Market$-0.521.89%
11/10/2014Before Market$-0.50-8.70%
08/11/2014---$-0.45-7.14%
05/12/2014---$-0.85-129.73%
03/24/2014---$-4.98-1,210.53%

More About Ultragenyx

Website
https://www.ultragenyx.com
Country
USA
Full Time Employees
1,294

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

“Ultragenyx Earnings” Can Refer to the Ultragenyx Earnings Date

Some people say “Ultragenyx earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Ultragenyx position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Ultragenyx Stock on the Earnings Date

If you own Ultragenyx stock (RARE) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Ultragenyx might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Ultragenyx shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Ultragenyx Earnings

You can contact us any time if you would like to ask questions about Ultragenyx earnings or anything else related to the stock market.